Anti-DRAK1 (NT) Antibody

ORDERING INFORMATION

Catalog No.: 2147

Size: 100ug IgG in PBS, pH 7.4, purified by immunoaffinity chromatography.

BACKGROUND

Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis have been identified and designated DRAK1 and DRAK2 for DAP kinase–related apoptosis-inducing protein kinases. DRAKs contain an N-terminal kinase domain and a C- terminal regulation domain. Overexpression of DRAK1 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases which mediate apoptosis through their catalytic activities.

DRAK1 is located in cell nuclei, and the mRNA for DRAK1 is ubiquitously expressed in human tissues.

SPECIFICATION SUMMARY

Antigen: Peptide corresponding to aa 5-19 of human DRAK1 (accession no. Q9UEE5).

Host Species: Rabbit

Stabilizers: None

Preservatives: 0.02% sodium azide.

SPECIFICITY

This antibody recognizes human DRAK1 (50kDa). No cross-reactivity with DRAK2, DAP or ZIP kinases.

For in vitro investigational use only. Not for use in therapeutic or diagnostic procedures.

APPLICATIONS

Immunoblotting : use at 1ug/ml.

Western blot analysis of DRAK1 in (A) MOLT4 and (B) A431 whole cell lysates with DRAK1 antibody at 1μg/ml.

Positive control: Whole cell lysate from A431 or MOLT4 cells.

Immunocytochemistry: use at 2ug/ml.

Immunocytochemical staining of MOLT4 cells using DRAK1 antibody at 2μg/ml.

These are recommended concentrations. Enduser should determine optimal concentrations for their applications.

DILUTION INSTRUCTIONS

Dilute in PBS or medium which is identical to that used in the assay system.

STORAGE AND STABILITY

This antibody is stable for at least one (1) year at -20oC. Avoid multiple freeze-thaw cycles.

>>> 更多资讯详情请访问蚂蚁淘商城